Oncolytics Biotech Net Change in Intangible Assets 2010-2025 | ONCY

Oncolytics Biotech net change in intangible assets from 2010 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.

Oncolytics Biotech Net Change in Intangible Assets 2010-2025 | ONCY

Oncolytics Biotech net change in intangible assets from 2010 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$229.7B
Amgen (AMGN)$153.5B
Gilead Sciences (GILD)$149.5B
Vertex Pharmaceuticals (VRTX)$96B
Bristol Myers Squibb (BMY)$93.5B
CSL (CSLLY)$83.2B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$57.9B
Alnylam Pharmaceuticals (ALNY)$57B
Argenex SE (ARGX)$39.1B
BioNTech SE (BNTX)$26.3B
Insmed (INSM)$23.9B
Royalty Pharma (RPRX)$20.3B
Biogen (BIIB)$18.8B
Incyte (INCY)$15.5B
Illumina (ILMN)$14.6B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.5B
Ascendis Pharma (ASND)$12B
BioMarin Pharmaceutical (BMRN)$10.9B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$7.9B
Halozyme Therapeutics (HALO)$7.7B
Exact Sciences (EXAS)$7.7B
Roivant Sciences (ROIV)$7.6B